vs
GYRE THERAPEUTICS, INC.（GYRE）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是GYRE THERAPEUTICS, INC.的1.9倍（$71.1M vs $37.2M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -3.7%，领先5.7%），GYRE THERAPEUTICS, INC.同比增速更快（33.4% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-5.8M），过去两年GYRE THERAPEUTICS, INC.的营收复合增速更高（17.0% vs -4.7%）
GYRE Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性血液系统恶性肿瘤和实体瘤的新型靶向疗法，聚焦精准肿瘤学领域以满足未被满足的患者医疗需求，主要在北美地区开展业务。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
GYRE vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.9倍
$37.2M
营收增速更快
GYRE
高出35.3%
-1.8%
净利率更高
RMAX
高出5.7%
-3.7%
自由现金流更多
RMAX
多$39.3M
$-5.8M
两年增速更快
GYRE
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $37.2M | $71.1M |
| 净利润 | $-1.4M | $1.4M |
| 毛利率 | 95.3% | — |
| 营业利润率 | 0.3% | 13.1% |
| 净利率 | -3.7% | 2.0% |
| 营收同比 | 33.4% | -1.8% |
| 净利润同比 | -340.1% | -75.2% |
| 每股收益（稀释后） | $-0.01 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GYRERMAX
| Q4 25 | $37.2M | $71.1M | ||
| Q3 25 | $30.6M | $73.2M | ||
| Q2 25 | $26.8M | $72.8M | ||
| Q1 25 | $22.1M | $74.5M | ||
| Q4 24 | $27.9M | $72.5M | ||
| Q3 24 | $25.5M | $78.5M | ||
| Q2 24 | $25.2M | $78.5M | ||
| Q1 24 | $27.2M | $78.3M |
净利润GYRERMAX
| Q4 25 | $-1.4M | $1.4M | ||
| Q3 25 | $5.9M | $4.0M | ||
| Q2 25 | $1.6M | $4.7M | ||
| Q1 25 | $3.7M | $-2.0M | ||
| Q4 24 | $569.0K | $5.8M | ||
| Q3 24 | $2.9M | $966.0K | ||
| Q2 24 | $4.5M | $3.7M | ||
| Q1 24 | $9.9M | $-3.4M |
毛利率GYRERMAX
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
营业利润率GYRERMAX
| Q4 25 | 0.3% | 13.1% | ||
| Q3 25 | 22.7% | 25.0% | ||
| Q2 25 | 8.1% | 19.3% | ||
| Q1 25 | 10.3% | 7.2% | ||
| Q4 24 | 2.4% | 5.9% | ||
| Q3 24 | 16.6% | 19.4% | ||
| Q2 24 | 12.7% | 20.6% | ||
| Q1 24 | 29.7% | 5.8% |
净利率GYRERMAX
| Q4 25 | -3.7% | 2.0% | ||
| Q3 25 | 19.4% | 5.4% | ||
| Q2 25 | 5.9% | 6.4% | ||
| Q1 25 | 16.9% | -2.6% | ||
| Q4 24 | 2.0% | 8.0% | ||
| Q3 24 | 11.2% | 1.2% | ||
| Q2 24 | 18.0% | 4.7% | ||
| Q1 24 | 36.6% | -4.3% |
每股收益（稀释后）GYRERMAX
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $0.03 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $52.4M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $106.0M | $452.4M |
| 总资产 | $166.1M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资GYRERMAX
| Q4 25 | $52.4M | $118.7M | ||
| Q3 25 | $60.0M | $107.5M | ||
| Q2 25 | $54.4M | $94.3M | ||
| Q1 25 | $29.9M | $89.1M | ||
| Q4 24 | $26.7M | $96.6M | ||
| Q3 24 | $25.1M | $83.8M | ||
| Q2 24 | $25.1M | $66.1M | ||
| Q1 24 | $37.4M | $82.1M |
总债务GYRERMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益GYRERMAX
| Q4 25 | $106.0M | $452.4M | ||
| Q3 25 | $101.9M | $448.1M | ||
| Q2 25 | $92.0M | $442.4M | ||
| Q1 25 | $68.1M | $433.5M | ||
| Q4 24 | $63.3M | $429.5M | ||
| Q3 24 | $63.2M | $423.1M | ||
| Q2 24 | $60.4M | $418.4M | ||
| Q1 24 | $56.6M | $412.0M |
总资产GYRERMAX
| Q4 25 | $166.1M | $582.5M | ||
| Q3 25 | $159.4M | $582.2M | ||
| Q2 25 | $152.6M | $574.8M | ||
| Q1 25 | $129.8M | $571.4M | ||
| Q4 24 | $125.4M | $581.6M | ||
| Q3 24 | $125.2M | $578.6M | ||
| Q2 24 | $120.9M | $571.4M | ||
| Q1 24 | $122.0M | $566.7M |
负债/权益比GYRERMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.6M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-5.8M | $33.5M |
| 自由现金流率自由现金流/营收 | -15.5% | 47.1% |
| 资本支出强度资本支出/营收 | 0.4% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-180.0K | $56.8M |
8季度趋势，按日历期对齐
经营现金流GYRERMAX
| Q4 25 | $-5.6M | $40.9M | ||
| Q3 25 | $4.7M | $17.7M | ||
| Q2 25 | $2.1M | $4.6M | ||
| Q1 25 | $-129.0K | $5.7M | ||
| Q4 24 | $-2.8M | $59.7M | ||
| Q3 24 | $1.7M | $17.6M | ||
| Q2 24 | $-5.5M | $15.9M | ||
| Q1 24 | $2.9M | $9.4M |
自由现金流GYRERMAX
| Q4 25 | $-5.8M | $33.5M | ||
| Q3 25 | $4.0M | $16.4M | ||
| Q2 25 | $1.8M | $2.9M | ||
| Q1 25 | $-251.0K | $4.0M | ||
| Q4 24 | $-2.8M | $53.0M | ||
| Q3 24 | $1.0M | $16.3M | ||
| Q2 24 | $-6.9M | $14.0M | ||
| Q1 24 | $2.7M | $6.8M |
自由现金流率GYRERMAX
| Q4 25 | -15.5% | 47.1% | ||
| Q3 25 | 13.1% | 22.4% | ||
| Q2 25 | 6.8% | 4.0% | ||
| Q1 25 | -1.1% | 5.3% | ||
| Q4 24 | -10.1% | 73.2% | ||
| Q3 24 | 4.1% | 20.8% | ||
| Q2 24 | -27.5% | 17.8% | ||
| Q1 24 | 9.8% | 8.6% |
资本支出强度GYRERMAX
| Q4 25 | 0.4% | 10.4% | ||
| Q3 25 | 2.2% | 1.8% | ||
| Q2 25 | 1.0% | 2.2% | ||
| Q1 25 | 0.6% | 2.3% | ||
| Q4 24 | 0.2% | 9.1% | ||
| Q3 24 | 2.7% | 1.7% | ||
| Q2 24 | 5.8% | 2.4% | ||
| Q1 24 | 0.9% | 3.3% |
现金转化率GYRERMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | 0.79× | 4.45× | ||
| Q2 25 | 1.32× | 0.97× | ||
| Q1 25 | -0.03× | — | ||
| Q4 24 | -4.85× | 10.28× | ||
| Q3 24 | 0.60× | 18.22× | ||
| Q2 24 | -1.21× | 4.29× | ||
| Q1 24 | 0.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GYRE
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
